Skip to main content
Clinical Trials/NCT04679584
NCT04679584
Recruiting
Not Applicable

COVIDOM: Longterm Morbidity of SARS-CoV-2 Infection and COVID-19 Disease - Consequences for Health Status and Quality of Life (NAPKON-POP)

University Hospital Schleswig-Holstein3 sites in 1 country2,000 target enrollmentNovember 16, 2020
ConditionsCOVID-19

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
COVID-19
Sponsor
University Hospital Schleswig-Holstein
Enrollment
2000
Locations
3
Primary Endpoint
Longterm morbidities and sequels of SARS-CoV-2 infections in the general population
Status
Recruiting
Last Updated
5 years ago

Overview

Brief Summary

COVID-19 is a novel disease caused by SARS-CoV-2 that primarily affects the lungs but also various other organs of the body already in early stages of the disease. Due to the multiple organ involvements in the acute phase, it is conceivable that - in a significant proportion of patients - longterm sequels in various organ systems might occur, thereby impacting the individual's health status and quality of life; and posing a relevant burden to the resources of the health care system

Assessment of SARS-CoV-2-longterm morbidity and sequels on the population level:

In order to identify and treat these sequels in a timely fashion and to get a sense of the prevalence of such SARS-CoV-2 sequels on the population level, it is important to collect follow-up data and to comprehensively re-examine a population-representative sample of SARS-CoV-2 infected individuals.

Within the COVIDOM study we will conduct deep clinical and biochemical phenotyping in population-representative samples in Germany. This will allow novel insights into disease pathogenesis and chronicity of virus infections.

Detailed Description

Background: COVID-19 is a novel disease caused by SARS-CoV-2. Severity of infection in the acute phase ranges from asymptomatic to critically ill and fatal courses of the disease. Besides the acute respiratory distress syndrome (ARDS), also thromboembolic events and acute damages of other organs are contributing to severe and critical courses of the disease in the acute phase of the infection. It is, however, largely unknown whether and to what extent different organs are affected in individuals with milder courses of the disease. Hypotheses: 1. Across all severity stages in the acute phase, SARS-CoV-2 infection causes longterm damages in various organ systems in a significant proportion of patients. 2. Beyond the damages directly caused by the infection, also the behavioral changes implemented to reduce the spread of the virus might impact an individual's health status and quality of life. 3. The infection itself and the pandemic in general results in increased use of health care resources. Methods: SARS-CoV-2 infected individuals in defined geographic regions will be contacted through the responsible health authorities and will be informed about the study and invited to participate. These individuals will presumably represent all severity grades in the initial phase of the infection (asymptomatic, uncomplicated, complicated, critical course of disease) and each of them will be offered a detailed clinical examination program that Includes structural and functional assessment of various organ systems (lungs, cardiovascular, CNS including smell/tase, liver), a comprehensive medical history, as well as psychological and psychiatric assessments.

Registry
clinicaltrials.gov
Start Date
November 16, 2020
End Date
December 31, 2030
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University Hospital Schleswig-Holstein
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • PCR-confirmed SARS-CoV-2 infection
  • living in one of the target areas
  • age at least 18 years
  • written informed consent

Exclusion Criteria

  • Acute SARS-CoV-2 infection or reinfection

Outcomes

Primary Outcomes

Longterm morbidities and sequels of SARS-CoV-2 infections in the general population

Time Frame: Preliminary results in 03/2021

Chronic organ impairments, especially of the lungs, heart, liver, central nervous system, smell and taste or psychological well-being bases on functional assessments (i.e. lung function including forced spirometry, bodyplethysmography, diffusing capacity for CO, FeNO, echocardiography, testing of smell and taste, neurological assessment, psychological assessment) and biomarker studies (blood, nasopharyngeal swabs, urin, stool)

Secondary Outcomes

  • Longterm quality of life of SARS-CoV-2 infected individuals recruited from the general population(Preliminary results in 03/2021)
  • Longterm health care utilization of SARS-CoV-2 infected individuals recruited from the general population(Preliminary results in 03/2021)

Study Sites (3)

Loading locations...

Similar Trials